skip to Main Content

February 15, 2013

Codexis to Participate in Informex USA 2013 Conference

-Company to Highlight its Enzymatic Technology Breakthroughs and
Market Opportunities in Fine Chemicals Sector-

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Feb. 15, 2013–
Codexis, Inc. (NASDAQ: CDXS), a developer of world-leading enzymes and
processes for the production of pharmaceuticals, biofuels and bio-based
chemicals, announced today that it will exhibit the Company’s enzymatic
approaches for the fine chemicals industry at the Informex USA 2013
Conference, being held at the Anaheim Convention Center in Anaheim,
Calif.
, from February 19-22, 2013.

The Company will use the opportunity to discuss its technology
breakthroughs that enable enzymatic processes to achieve greater cost
savings and speed to market for a variety of fine and specialty
chemicals.

“Codexis continues to show that its unique and differentiated enzymatic
approach allows for exciting opportunities across the pharmaceutical and
chemical fields,” said John Nicols, President and CEO of Codexis. “Our
advanced enzymatic processes allow for more efficient production than
traditional chemistry approaches. We look forward to further
demonstrating the large impact of our technology platform and are highly
focused on accelerating the adoption of our enzymatic approach through
partnerships among leading players in the fine chemicals industry.”

Exhibit Details

Codexis’ exhibit at the conference will be located in Booth 2423H of the
Green Exchange Gallery at the Anaheim Convention Center from February
19-22, 2013
.

About Codexis, Inc.

Codexis, Inc. is a developer of world-leading enzymes and processes for
the production of pharmaceuticals, biofuels and bio-based chemicals.
Codexis’ product lines include CodeXyme® cellulase enzymes and CodeXol™
detergent alcohol. Partners and customers include global leaders such as
Merck, Pfizer and Arch Pharmalabs. For more information, see www.codexis.com.

Forward Looking Statements

This press release contains forward-looking statements relating to
potential commercial opportunities for Codexis’ technologies in the
pharmaceutical and fine chemicals fields. You should not place undue
reliance on these forward-looking statements because they involve known
and unknown risks, uncertainties and other factors that are, in some
cases, beyond our control and could materially affect actual results.
Factors that could materially affect actual results include our
dependence on a limited number of products in our pharmaceutical
business; potential adverse affects to our business if our customers’
pharmaceutical products are not received well in the markets; and our
ability to develop and commercialize new products for the pharmaceutical
market. Additional factors that could materially affect actual results
can be found in Codexis’ Quarterly Report on Form 10-Q for the period
ended September 30, 2012 filed with the Securities and Exchange
Commission
on November 7, 2012, including under the caption “Risk
Factors.” Codexis expressly disclaims any intent or obligations to
update these forward-looking statements, except as required by law.

Source: Codexis, Inc.

Stern Investor Relations
Paul Cox, 212-362-1200
ir@codexis.com

Back To Top
Close search
Search